ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS

a technology of bcl-2 and induction of apoptosis, which is applied in the field of anti-bcl-2 and its use in the induction of apoptosis, to achieve the effect of better and more effective induction of apoptosis

Inactive Publication Date: 2015-01-15
CARMEL HAIFA UNIV ECONOMIC
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes an antagonist of a protein called Bcl-2, which is involved in the regulation of cell death. The antagonist is called ARTS and it can be used alone or in combination with another compound called a BH3-mimetic. The invention provides a method for treating disorders associated with Bcl-2 over-expression, a marker called ARTS for assessing the effectiveness of BH3-mimetic treatment, and a diagnostic tool for identifying suitable subjects for treatment. The technical effects of the patent include improved methods for treating Bcl-2 over-expressing disorders and enhanced understanding of the molecular mechanisms involved in cell death regulation.

Problems solved by technology

It has been shown that deregulation of the apoptosis pathway can result in various pathologic conditions, including cancer (Fuchs and Steller, 2011).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS
  • ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS
  • ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS

Examples

Experimental program
Comparison scheme
Effect test

example 1

Bcl-2 Protein Levels are Down-Regulated During Apoptosis Induced by STS and Etoposide

[0340]Bcl-2 is an anti-apoptiotic factor and thus at the onset of apoptosis, the anti-apoptotic function of Bcl-2 has to be overcome. This usually occurs through interactions between Bcl-2 and the pro-apoptotic members of the Bcl-2 family (Youle and Strasser, 2008).

[0341]The role of Bcl-2 during apoptosis was studied in different cell lines and under various apoptotic conditions. The results presented in FIG. 1 show that Bcl-2 levels are down regulated upon induction of apoptosis with Staurosporine (STS) or Etoposide in different cell lines and mouse embryonic fibroblasts (MEFs).

[0342]These results are in accordance with previous data showing that Bcl-2 levels are down regulated during apoptosis induced by treatment with cisplatin, ursolic acid, Se-methylselenocystein, TNFα and ROS.

[0343]Specifically, FIGS. 1A to 1I display western blots of whole cell lysate using Bcl-2 antibodies. The levels of Bcl...

example 2

ARTS is Required for Down-Regulation of Bcl-2 Levels

[0352]Bcl-2 is known to be localized at the outer membrane of mitochondria (MOM), the endoplasmic reticulum and nuclear envelop (Kaufmann et al., 2003).

[0353]To further determine the cellular localization of Bcl-2 under apoptotic and non-apoptotic conditions, Immunofluorescence assay was conducted. HeLa cells were transfected with Bcl-2 and the cells were treated with the apoptotic inducer Staurosporine (STS) for 60 and 180 minutes.

[0354]Cells in which Bcl-2 is detected at mitochondria (co-localize with MitoTracker), or at the cytosol (showing diffused pattern of staining) were counted. FIGS. 3A to 3C show that at time 0, all Bcl-2 was localized to the mitochondria. Sixty minutes following STS treatment, 63% of cells exhibited Bcl-2 in their cytosol, and following 180 minutes of STS treatment, most of the cells (94%) exhibited Bcl-2 in the cytosol.

[0355]It has been recently shown by some of the inventors that similarly to Bcl-2, AR...

example 3

Bcl-2, ARTS and XIAP Form a Complex

[0362]The mechanism by which ARTS regulates Bcl-2 levels was further tested using a pull-down assay in COS-7 cells which were co-transfected with Bcl-2 and ARTS expression vectors. Pull-down assays were performed using agarose anti-myc beads followed by Western blot analysis using mouse anti-ARTS and anti-Bcl-2 antibodies.

[0363]The results presented in FIG. 4A show that ARTS forms a complex with Bcl-2. Interestingly, the complex is degraded upon induction of apoptosis with Etopo.

[0364]It has been previously shown by part of the inventors that ARTS binds directly to XIAP and functions as antagonist to XIAP both in vitro and in vivo (Bornstein et al., 2011; Edison et al., 2012a; Garcia-Fernandez et al., 2010; Garrison et al., 2010; Gottfried et al., 2004). XIAP is an E3-ligase and this activity is essential for its anti-apoptotic activity; Schile et al., 2008).

[0365]Because both ARTS and Bcl-2 are localized at the MOM, and since ARTS binds to XIAP, t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides an antagonist of a Bcl-2 pro survival protein containing a BH3-like domain. The antagonist of the invention comprises ARTS and any fragment or peptide that comprises a BH3-like domain. The invention further provides compositions, combined compositions and kits as well as methods for treating Bcl-2 over-expressing disorders.

Description

PRIOR ART[0001]References considered to be relevant as background to the presently disclosed subject matter are listed below:[0002]Fuchs, Y., and H. Steller. Cell. 147:1-17 (2011).[0003]Gottfried, Y., A. et al., EMBO J. 23:1627-35 (2004). Larisch, S., et al., Nat Cell Biol. 2:915-21 (2000).[0004]Edison, N., D. et al. Cell Death Differ. 19:356-68 (2012b).[0005]Bornstein, B., Y. et al., Apoptosis 16:869-881 (2011).[0006]Reingewertz, T. H., et al., PLoS One. 6:e24655 (2011).[0007]Adams, J. M., and S. Cory. Trends Biochem Sci. 26:61-6 (2001).[0008]Youle, R. J., and A. Strasser. Nat Rev Mol Cell Biol. 9:47-59 (2008).[0009]Happo, L., A. et al., J Cell Sci. 125:1081-7 (2012).[0010]Robertson, L. E., et al., Leukemia. 10:456-9 (1996).[0011]Oltersdorf, T. S. W. et al., Nature, 435:677-81 (2005).[0012]Schile, A. J., M. Genes Dev. 22:2256-66 (2008).[0013]Lotan, R., A. et al., J Biol Chem. 280:25802-10 (2005).[0014]Kerppola, T. K. Nat Protoc. 1:1278-86 (2006).[0015]Bader, M., and H. Steller. Cur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/47G01N33/68
CPCC07K14/4747G01N33/68G01N2333/4704A61K38/00G01N33/6893G01N2510/00G01N2800/52
Inventor LARISCH, SARIT
Owner CARMEL HAIFA UNIV ECONOMIC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap